Persistent Antibody Clonotypes Dominate the Serum Response to Influenza over Multiple Years and Repeated Vaccinations.
anti-hemagglutinin antibodies
humoral immunity
immunological imprinting
influenza vaccine response
longitudinal profiling
persistent antibodies
serum antibody repertoire
Journal
Cell host & microbe
ISSN: 1934-6069
Titre abrégé: Cell Host Microbe
Pays: United States
ID NLM: 101302316
Informations de publication
Date de publication:
13 Mar 2019
13 Mar 2019
Historique:
received:
16
07
2018
revised:
02
11
2018
accepted:
18
01
2019
pubmed:
24
2
2019
medline:
9
11
2019
entrez:
24
2
2019
Statut:
ppublish
Résumé
Humans are repeatedly exposed to influenza virus via infections and vaccinations. Understanding how multiple exposures and pre-existing immunity impact antibody responses is essential for vaccine development. Given the recent prevalence of influenza H1N1 A/California/7/2009 (CA09), we examined the clonal composition and dynamics of CA09 hemagglutinin (HA)-reactive IgG repertoire over 5 years in a donor with multiple influenza exposures. The anti-CA09 HA polyclonal response in this donor comprised 24 persistent antibody clonotypes, accounting for 72.6% ± 10.0% of the anti-CA09 HA repertoire over 5 years. These persistent antibodies displayed higher somatic hypermutation relative to transient serum antibodies detected at one time point. Additionally, persistent antibodies predominantly demonstrated cross-reactivity and potent neutralization toward a phylogenetically distant H5N1 A/Vietnam/1203/2004 (VT04) strain, a feature correlated with HA stem recognition. This analysis reveals how "serological imprinting" impacts responses to influenza and suggests that once elicited, cross-reactive antibodies targeting the HA stem can persist for years.
Identifiants
pubmed: 30795981
pii: S1931-3128(19)30048-4
doi: 10.1016/j.chom.2019.01.010
pmc: PMC6417944
mid: NIHMS1519399
pii:
doi:
Substances chimiques
Antibodies, Viral
0
H1N1 virus hemagglutinin
0
Hemagglutinin Glycoproteins, Influenza Virus
0
Immunoglobulin G
0
Influenza Vaccines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
367-376.e5Subventions
Organisme : European Research Council
ID : 670955
Pays : International
Organisme : NIAID NIH HHS
ID : P01 AI089618
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2019 Elsevier Inc. All rights reserved.
Références
Annu Rev Biochem. 2000;69:531-69
pubmed: 10966468
Philos Trans R Soc Lond B Biol Sci. 2001 Dec 29;356(1416):1861-70
pubmed: 11779385
Science. 2002 Dec 13;298(5601):2199-202
pubmed: 12481138
Nat Immunol. 2006 May;7(5):449-55
pubmed: 16622432
BMC Bioinformatics. 2007 Feb 09;8:51
pubmed: 17291342
Nature. 2008 May 29;453(7195):667-71
pubmed: 18449194
Nat Struct Mol Biol. 2009 Mar;16(3):265-73
pubmed: 19234466
Eur J Immunol. 2009 May;39(5):1260-70
pubmed: 19404981
Influenza Other Respir Viruses. 2007 May;1(3):105-12
pubmed: 19453415
Science. 2009 Jul 10;325(5937):197-201
pubmed: 19465683
Vaccine. 2010 Apr 30;28(20):3582-7
pubmed: 20298818
J Clin Invest. 2010 May;120(5):1663-73
pubmed: 20389023
Science. 2010 Aug 27;329(5995):1060-4
pubmed: 20647428
N Engl J Med. 2010 Nov 18;363(21):2036-44
pubmed: 21083388
Clin Vaccine Immunol. 2011 Mar;18(3):469-76
pubmed: 21209157
J Exp Med. 2011 Jan 17;208(1):181-93
pubmed: 21220454
Science. 2011 Aug 12;333(6044):850-6
pubmed: 21798894
Proc Natl Acad Sci U S A. 2011 Aug 23;108(34):14216-21
pubmed: 21825125
PLoS One. 2011;6(10):e25797
pubmed: 22039424
PLoS One. 2012;7(4):e35497
pubmed: 22558161
Proc Natl Acad Sci U S A. 2012 Jun 5;109(23):9047-52
pubmed: 22615367
Nature. 2012 Sep 27;489(7417):526-32
pubmed: 22982990
Annu Rev Immunol. 2013;31:705-42
pubmed: 23330954
Proc Natl Acad Sci U S A. 2013 Feb 19;110(8):2993-8
pubmed: 23382245
J Virol. 2013 Jun;87(12):7149-54
pubmed: 23552413
Proc Natl Acad Sci U S A. 2014 Feb 11;111(6):2259-64
pubmed: 24469811
Anal Chem. 2014 May 20;86(10):4758-66
pubmed: 24684310
Nat Commun. 2014 Apr 10;5:3614
pubmed: 24717798
Nature. 2014 Dec 18;516(7531):418-22
pubmed: 25296253
J Infect Dis. 2015 Apr 1;211(7):1051-9
pubmed: 25336731
Science. 2014 Nov 21;346(6212):996-1000
pubmed: 25414313
Curr Opin Chem Biol. 2015 Feb;24:112-20
pubmed: 25461729
Nat Med. 2015 Jan;21(1):86-91
pubmed: 25501908
J Virol. 2015 Mar;89(6):3308-17
pubmed: 25589639
Nat Rev Drug Discov. 2015 Mar;14(3):167-82
pubmed: 25722244
PLoS Biol. 2015 Mar 03;13(3):e1002082
pubmed: 25734701
Cell. 2015 May 21;161(5):1026-1034
pubmed: 25959776
Nat Med. 2015 Sep;21(9):1065-70
pubmed: 26301691
Science. 2015 Sep 18;349(6254):1301-6
pubmed: 26303961
Vaccine. 2016 Jan 20;34(4):495-502
pubmed: 26706277
Cell Rep. 2015 Dec 29;13(12):2842-50
pubmed: 26711348
Nat Protoc. 2016 Mar;11(3):429-42
pubmed: 26844430
Cell. 2016 Jul 28;166(3):596-608
pubmed: 27453466
Cell. 2016 Jul 28;166(3):609-623
pubmed: 27453470
Nat Immunol. 2016 Oct;17(10):1226-34
pubmed: 27525369
PLoS Pathog. 2016 Aug 18;12(8):e1005806
pubmed: 27537358
Nat Med. 2016 Dec;22(12):1456-1464
pubmed: 27820605
Science. 2016 Nov 11;354(6313):722-726
pubmed: 27846599
Nat Immunol. 2017 Apr;18(4):456-463
pubmed: 28192417
Nat Immunol. 2017 Apr;18(4):464-473
pubmed: 28192418
Curr Opin Virol. 2017 Jun;24:60-69
pubmed: 28527859
J Mol Biol. 2017 Aug 18;429(17):2694-2709
pubmed: 28648617
Cold Spring Harb Perspect Biol. 2018 Jul 2;10(7):null
pubmed: 28663210
Sci Immunol. 2017 Jan 27;2(7):null
pubmed: 28783671
Immunity. 2018 Jan 16;48(1):174-184.e9
pubmed: 29343437
Immunity. 1998 Mar;8(3):363-72
pubmed: 9529153